As a result, chemo-immunotherapy (CT-ICI) combinations have become a standard of care as first-line therapy among patients with metastatic NSCLC without druggable molecular alterations, regardless of PD-L1 tumor expression. This evidence concerns the gene CD274 and neoplasm.